Renoprotection Provided by Additional Diuretic Treatment in Partially Nephrectomized Ren-2 Transgenic Rats Subjected to the Combined RAS and ETA Blockade

被引:1
作者
Vaneckova, Ivana [1 ]
Hojna, Silvie [1 ]
Vemerova, Zdenka [2 ]
Kadlecova, Michaela [1 ]
Rauchova, Hana [1 ]
Kompanowska-Jezierska, Elzbieta [3 ]
Vanourkova, Zdenka [4 ]
Cervenka, Ludek [4 ]
Zicha, Josef [1 ]
机构
[1] Czech Acad Sci, Inst Physiol, Dept Expt Hypertens, Prague, Czech Republic
[2] Charles Univ Prague, Fac Med 3, Dept Pathol, Prague, Czech Republic
[3] Polish Acad Sci, Mossakowski Med Res Ctr, Dept Renai & Body Fluid Physiol, Warsaw, Poland
[4] Inst Clin & Expt Med, Prague, Czech Republic
关键词
hydrochlorothiazide; renoprotection; nephrectomy; atrasentan; chronic kidney disease; losartan; trandolapril; CHRONIC KIDNEY-DISEASE; RENIN-ANGIOTENSIN SYSTEM; RECEPTOR BLOCKADE; ENDOTHELIN ANTAGONISTS; HYPERTENSION; PROGRESSION; DRUGS; MODEL;
D O I
10.3389/fphys.2019.01145
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Objective: Our previous study in heterozygous Ren-2 transgenic rats (TGR) demonstrated that long-term treatment with endothelin receptor A (ETA) blocker atrasentan added to the renin-angiotensin system (RAS) blockade had renoprotective effects in a model of chronic kidney disease (CKD) induced by partial nephrectomy. Since ETA blockade is known to cause edema, we were interested whether diuretic treatment added to this therapy would be beneficial. Design and Methods: Partial nephrectomy (NX) was performed at the age of 3 months in TGR rats which were subjected to: (i) RAS blockade alone (angiotensin receptor blocker losartan and angiotensin converting enzyme inhibitor trandolapril), (ii) combined RAS (losartan and trandolapril) and ETA receptor blockade (atrasentan), or (iii) diuretic (hydrochlorothiazide) added to the combined RAS + ETA blockade for 50 weeks following NX. Results: At the end of the study systolic blood pressure and cardiac hypertrophy were similarly decreased in all treated groups. Survival was significantly improved by ETA receptor blockade added to RAS blockade with no further effects of diuretic treatment. However, additional diuretic treatment combined with RAS + ETA blockade decreased body weight and had beneficial renoprotective effects - reductions of both kidney weight and kidney damage markers. Proteinuria gradually increased in rats treated with RAS blockade alone, while it was substantially lowered by additional ETA blockade. In rats treated with additional diuretic, proteinuria was progressively reduced throughout the experiment. Conclusion: A diuretic added to the combined RAS and ETA blockade has late renoprotective effects in CKD induced by partial nephrectomy in Ren-2 transgenic rats. The diuretic improved: renal function (evaluated as proteinuria and creatinine clearance), renal morphology (kidney mass, glomerular volume), and histological markers of kidney damage (glomerulosclerosis index, tubulointerstitial injury).
引用
收藏
页数:10
相关论文
共 45 条
  • [1] An association of losartan-hydrochlorothiazide, but not losartan-furosemide, completely arrests progressive injury in the remnant kidney
    Alarcon Arias, Simone Costa
    Souza, Renata Alves
    Avancini Costa Malheiros, Denise Maria
    Fanelli, Camilla
    Fujihara, Clarice Kazue
    Zatz, Roberto
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2016, 310 (02) : F135 - F143
  • [2] Regression of Albuminuria and Hypertension and Arrest of Severe Renal Injury by a Losartan-Hydrochlorothiazide Association in a Model of Very Advanced Nephropathy
    Alarcon Arias, Simone Costa
    Valente, Carla Perez
    Machado, Flavia Gomes
    Fanelli, Camilla
    Taemi Origassa, Clarice Silvia
    de Brito, Thales
    Saraiva Camara, Niels Olsen
    Avancini Costa Malheiros, Denise Maria
    Zatz, Roberto
    Fujihara, Clarice Kazue
    [J]. PLOS ONE, 2013, 8 (02):
  • [3] The hyperfiltration theory: A paradigm shift in nephrology
    Brenner, BM
    Lawler, EV
    Mackenzie, HS
    [J]. KIDNEY INTERNATIONAL, 1996, 49 (06) : 1774 - 1777
  • [4] Developing Treatments for Chronic Kidney Disease in the 21st Century
    Breyer, Matthew D.
    Susztak, Katalin
    [J]. SEMINARS IN NEPHROLOGY, 2016, 36 (06) : 436 - 447
  • [5] The Dilemma of Dual Renin-Angiotensin System Blockade in Chronic Kidney Disease: Why Beneficial in Animal Experiments But Not in the Clinic?
    Chabova, V. Certikova
    Cervenka, L.
    [J]. PHYSIOLOGICAL RESEARCH, 2017, 66 (02) : 181 - 192
  • [6] Addition of ETA receptor blockade increases renoprotection provided by renin-angiotensin system blockade in 5/6 nephrectomized Ren-2 transgenic rats
    Chabova, Vera Certikova
    Vernerova, Zdenka
    Kujal, Petr
    Huskova, Zuzana
    Skaroupkova, Petra
    Tesar, Vladimir
    Kramer, Herbert J.
    Kompanowska-Jezierska, Elzbieta
    Walkowska, Agnieszka
    Sadowski, Janusz
    Cervenka, Ludek
    Vaneckova, Ivana
    [J]. LIFE SCIENCES, 2014, 118 (02) : 297 - 305
  • [7] Parallel-Group 8-Week Study on Chlorthalidone Effects in Hypertensives With Low Kidney Function
    Cirillo, Massimo
    Marcarelli, Fabiana
    Mele, Alessandra A.
    Romano, Massimo
    Lombardi, Cinzia
    Bilancio, Giancarlo
    [J]. HYPERTENSION, 2014, 63 (04) : 692 - 697
  • [8] Cohen JW., 1988, STAT POWER ANAL BEHA, DOI 10.4324/9780203771587
  • [9] Endothelin in Nondiabetic Chronic Kidney Disease: Preclinical and Clinical Studies
    Culshaw, Geoff J.
    MacIntyre, Iain M.
    Dhaun, Neeraj
    Webb, David J.
    [J]. SEMINARS IN NEPHROLOGY, 2015, 35 (02) : 176 - 187
  • [10] Therapeutic potential of endothelin receptor antagonism in kidney disease
    Czopek, Alicja
    Moorhouse, Rebecca
    Webb, David J.
    Dhaun, Neeraj
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2016, 310 (05) : R388 - R397